The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

Clinical experience has confirmed the anorexic effect of Glucagon-like-peptide 1 (GLP-1) mimetics in comparison to DPP-4 inhibitors. A possible mechanism of this effect might be associated with changes in food choices, as suggested by animal studies. It has been shown that functional magnetic resonance imaging (fMRI) of the brain is a valuable tool in obesity research and can be used to study the response of several brain regions to the visual presentation of preferred in comparison to non preferred food items and to non food items The aim of this study is to search for possible effects of liraglutide in comparison to placebo on 1. food choices and 2. changes in brain function as evidenced by fMRI in healthy volunteers.

Findings of this study will help not only to get deeper insight into the mechanism of the anorexic effect of GLP-1 mimetics, but also into the regulation of food choices per se. In the future, it is planned to extend the results of this study in normal weight volunteers to obese diabetic subjects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Male healthy volunteers

• Age 20-40

• Non-smokers

• Normal body weight (body mass index 19 -25 kg/m2)

• Right handed

• Signed informed consent

• Willingness and ability to comply with the protocol

Exclusion Criteria:

• Any history of or current drug abuse including alcohol consumption on a regular basis or binge drinking

• Any history of or current psychiatric disease, including any eating disorder, as assessed by structured interview

• Any history of dieting

• Any condition interfering with fMRI measurements such as ferromagnetic implants or claustrophobia

• Any evidence of relevant renal, liver, thyroid, cardiovascular, or respiratory illness at screening examination

• Any acute illness necessitating medical treatment during the last 3 weeks before study entry, any permanent intake of medication

• Any study participation in the last 3 months

• HIV, hepatitis B or C positive

• Any disease considered relevant for proper performance of the study or risks to the participant, at the discretion of the investigator